Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IMCgp100 (tebentafusp) vs Investigator's Choice in Advanced Uveal Melanoma
NCT03070392Phase 2Completed
- Sponsor
- Immunocore
- Start
- Oct 2017
- Primary completion
- Oct 2020
- Modality
- Bispecific Antibodies, TCR-Engineered T Cells, Fc-Fusion Proteins
- Countries
- 14
01
Overview
A Phase 2 trial of tebentafusp in Uveal melanoma (UM), sponsored by Immunocore. Started Oct 2017; status: completed.
02
Drugs
tebentafusp
03
Conditions
Uveal melanoma (UM)
Beyond the preview
Go deeper on NCT03070392.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03070392.